106261-27-2

Basic information

• Product Name: 4-PIPERAZIN-1-YLTHIENO[3,2-C]PYRIDINE
• Synonyms: 4-PIPERAZIN-1-YLTHIENO[3,2-C]PYRIDINE;4-(1-PIPERAZINYL)THIENO[3,2-C]PYRIDINE;4-Piperazin-1-ylthieno[3,2-c]pyridinetrihydrochloride;1-{thieno[3,2-c]pyridin-4-yl}piperazine
• CAS NO: 106261-27-2
• Molecular Formula: C₁₁H₁₃N₃S
• Molecular Weight: 219.31
• Mol File: 106261-27-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 422.2°Cat760mmHg
• Flash Point: 209.1°C
• Appearance: /
• Density: 1.256g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: 4-PIPERAZIN-1-YLTHIENO[3,2-C]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERAZIN-1-YLTHIENO[3,2-C]PYRIDINE(106261-27-2)
• EPA Substance Registry System: 4-PIPERAZIN-1-YLTHIENO[3,2-C]PYRIDINE(106261-27-2)

Safety Data

• Hazardous Substances Data: 106261-27-2(Hazardous Substances Data)

Usage

General Description

4-PIPERAZIN-1-YLTHIENO[3,2-C]PYRIDINE, also known as TASP0334548, is a chemical compound with potential pharmaceutical properties. It is a small molecule inhibitor of protein kinase RIOK2, which plays a role in cell growth and cancer progression. TASP0334548 has been studied for its potential use in cancer treatment, particularly in targeting aggressive and drug-resistant cancer cells. Its ability to inhibit RIOK2 makes it a promising candidate for the development of novel anti-cancer drugs. Further research is needed to fully understand the therapeutic potential and safety profile of TASP0334548 for clinical use.

InChI:InChI=1/C11H13N3S/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2

Upstream product

• 110-85-0 piperazine 
• 27685-94-5 4-chlorothieno[3,2-c]pyridine 
• 123-51-3 i-Amyl alcohol 
• 71-41-0 pentan-1-ol 
• 27685-92-3 4-oxo-4,5-dihydrothieno[3,2-c]pyridine 

Downstream Products

• 1352737-07-5 trans-{4-[2-(4-thieno[3,2-c]pyridin-4-yl-piperazin-1-yl)-ethyl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 106260-94-0 α-(4-fluorophenyl)-4-(thieno<3,2-c>pyridin-4-yl)-1-piperazinebutanol 
• 119924-12-8 4-<4-(thieno<3,2-c>pyridin-4-yl)-1-piperazinyl>-1-(4-fluorophenyl)-1-butanone 
• 119924-11-7 4-(4-{3-[2-(4-Fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-piperazin-1-yl)-thieno[3,2-c]pyridine 
• 106260-99-5 4-[4-(4-Thieno[3,2-c]pyridin-4-yl-piperazin-1-yl)-butyl]-thiomorpholine-3,5-dione; compound with toluene-4-sulfonic acid 

Relevant articles and documents

FLUORINATED DERIVATIVE OF QUINOLIN-2(1H)-ONE, METHOD FOR PREPARING THE SAME AND USE THEREOF AS A SYNTHESIS INTERMEDIATE

The invention relates to a fluorinated derivate of quinolin-2(1H)-one (I), to a method for preparing the same, and to the use thereof as an intermediate in the synthesis of 7-fluoro-2-oxo-4-[2-[4-[thieno[3,2-c]pyridine-4-yl)piperazin-1-yl]ethyl]-1,2-dihyd

PYRIMIDINE DERIVATIVE

This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0 - 4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.

The Thienopyridine and Furopyridine Rings: New Pharmacophores with Potential Antipsychotic Activity

Two new arylpiperazine derivatives, the 4-(1-piperazinyl)thieno- and -furopyridine ring systems, have been synthesized and appended via tetramethylene chains to various imide rings.Target compounds from each series were found to have significant activity in the blockade of apomorphine stereotypy and apomorphine-induced climbing, the Sidman avoidance response, and the conditioned avoidance response.In addition, while potent affinity for serotonin 5-HT1 and 5-HT2 receptors was observed for both the thieno- and furopyridine derivatives,the interaction of these molecules with the dopamine D2 receptor was weak.Electrophysiological studies of the lead prototypes from each series, involving compounds 22 and 33, indicate these two molecules have distinctively different effects on dopamine neurons in areas A9 and A10.Despite the similarity these molecules share in their behavioral indices of antipsychotic acivity, it is likely that the thieno- and furopyridine rings employ different mechanisms to achieve this convergence of biological effects.